Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI
Status:
Recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
Selection of developmentally competent oocytes enhances IVF efficiency. Usually, oocyte
quality is determined based on its nuclear maturation and the presence of specific
cytoplasmic and extracytoplasmic morphologic features. Gonadotropin-releasing hormone
agonists (GnRH Agonists) and gonadotropin-releasing hormone antagonists (GnRH Antagonists)
are used during controlled ovarian stimulation (COS) protocols in order to prevent premature
luteinizing hormone (LH) surge and premature ovulation. However, GnRH receptors are also
expressed in extra-pituitary tissues such as ovary, but it is still unknown whether the type
of GnRH analogues used during COS could affect the oocyte morphology in polycystic ovary
syndrome (PCOS) patients. The aim of this prospective, non-randomised, open-label, clinical
trial is to compare the effects of two pituitary suppression regimens; GnRH Agonist-Long
Protocol and GnRH Antagonist-Flexible Protocol on oocyte morphology in PCOS patients during
IVF/ICSI.